Unleashing the potential of mRNA therapeutics with high-quality bioreagents and optimized in vitro transcription

Cell & Gene Therapy Insights 2023; 9(10), 1545

DOI: 10.18609/cgti.2023.202

Published: 20 December 2023
Jessica Madigan

Watch the video or view the poster to learn more about:

  • Benefits of using cGMP grade DTT and optimized in vitro transcription conditions
  • Strategies to overcome common challenges in analytical testing of product and raw materials, and product purity
  • How to source the BIOVECTRA portfolio through Thermo Fisher Scientific

Jessica Madigan, BSc (Chemistry, 2008), has over 15 years of experience focused on nucleic acid manufacturing and development. Jessica played a key role at start-up CDMO leading to successful launch of mRNA, plasmid, capping analogs, and modified nucleotide products. Jessica also holds a Project Management Professional (PMP) Certification and successfully managed over 30 API manufacturing projects for mRNA early phase clinical trials. At BIOVECTRA (2022–present), Jessica supports business development efforts for pDNA, mRNA, LNP formulation and fill/finish services.